High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: A phase II study
- 1 July 1992
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 3 (7) , 577-578
- https://doi.org/10.1093/oxfordjournals.annonc.a058266
Abstract
Eighteen patients with progressive disseminated, platinum-resistant germ cell tumors were treated with epi-rubicin 135 mg/m2, every 3 weeks. One patient had stable disease, 17 developed progression. Myelosuppression was dose-limiting. One patient died of neutropenic septicemia. High-dose epirubicin is not active against platinum-resistant germ cell cancer.Keywords
This publication has 4 references indexed in Scilit:
- Treatment of refractory testis cancer: Salvage or savage chemotherapy?European Journal of Cancer and Clinical Oncology, 1991
- Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: Long-term follow-upEuropean Journal of Cancer and Clinical Oncology, 1991
- Treatment of testicular cancer: a new and improved model.Journal of Clinical Oncology, 1990
- High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: A phase II studyAnnals of Oncology, 1990